biostudies-literatureKhaki ARNCATS NIH HHSNational Cancer InstituteNCI NIH HHSWellcome Trust464-472https://www.ebi.ac.uk/biostudies/studies/S-EPMC8169524biostudies-literatureUnknown4(3)<h4>Background</h4>While immune checkpoint inhibitors (ICIs) are approved in the first-line (1L) setting for cisplatin-unfit patients with programmed death-ligand 1 (PD-L1)-high tumors or for platinum (cisplatin/carboplatin)-unfit patients, response rates remain modest and outcomes vary with no clinically useful biomarkers (except for PD-L1).<h4>Objective</h4>We aimed to develop a prognostic model for overall survival (OS) in patients receiving 1L ICIs for advanced urothelial cancer (aUC) in a multicenter cohort study.<h4>Design, setting, and participants</h4>Patients treated with 1L ICIs for aUC across 24 institutions and five countries (in the USA and Europe) outside clinical trials were included in this study.<h4>Outcome measurements and statistical analysis</h4>We used a stepwise, hypoEuropean urology oncologyA New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors.PMC8169524T32 CA009515PS3416UL1 TR001863UL1 TR002319Agarwal NKumar VLythgoe MPYu EYAlva AZakharia YSantos VZakopoulou RDrakaki AGrivas PLiu SCarril-Ajuria LDe Kouchkovsky ICastellano DGartrell BAMurgic JLi ANelson ATripathi AIsaacsson Velho PJoshi MLyman GHFrobe AMoses MMorales-Barrera RPark JKoshkin VJain JHahn NAlonso Buznego LDiamantopoulos LNStewart TGalsky MDBilen MABamias ASonpavde GMiller NJBarata PKhaki ARRodriguez-Vida ADuran IPinato DJSankin AHoimes CJShreck EShankaran VDevitt MfalseA New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors.<h4>Background</h4>While immune checkpoint inhibitors (ICIs) are approved in the first-line (1L) setting for cisplatin-unfit patients with programmed death-ligand 1 (PD-L1)-high tumors or for platinum (cisplatin/carboplatin)-unfit patients, response rates remain modest and outcomes vary with no clinically useful biomarkers (except for PD-L1).<h4>Objective</h4>We aimed to develop a prognostic model for overall survival (OS) in patients receiving 1L ICIs for advanced urothelial cancer (aUC) in a multicenter cohort study.<h4>Design, setting, and participants</h4>Patients treated with 1L ICIs for aUC across 24 institutions and five countries (in the USA and Europe) outside clinical trials were included in this study.<h4>Outcome measurements and statistical analysis</h4>We used a stepwise, hypo2021-01-01T00:00:00Z2021 Jun2025-04-04T20:15:40.678Z2025-04-04T20:15:40.678ZS-EPMC81695243342394510.1016/j.euo.2020.12.006